Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety

2018 ◽  
Vol 103 (9) ◽  
pp. 1332-1336 ◽  
Author(s):  
Hyun Goo Kang ◽  
Eun Young Choi ◽  
Suk Ho Byeon ◽  
Sung Soo Kim ◽  
Hyoung Jun Koh ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Case Series ◽  
Therapeutic Effects ◽  
Type I ◽  
Intravitreal Ranibizumab ◽  
Retrospective Case ◽  
Major Complications ◽  
Anatomical Outcomes

Background/AimsTo compare the efficacy, anatomical outcomes and complications of intravitreal ranibizumab with those of laser photocoagulation for retinopathy of prematurity (ROP).MethodsThis is a retrospective case series of 314 eyes from 165 infants diagnosed with type I ROP and treated with either laser photocoagulation (161 eyes) or intravitreal ranibizumab (0.25 mg/0.025 mL) injection (153 eyes) between January 2006 and December 2016 in a tertiary referral-based hospital. The main outcome was the rate of recurrence requiring additional treatment. Secondary outcomes included the incidence of major complications and final refractive error.ResultsThe mean follow-up was 36.3±31.9 months. Recurrences requiring further intervention were noted in 22 (13.7%) laser-treated and 15 (9.8%) ranibizumab-treated eyes (p=0.196). Retinal detachment (8 vs 1, p=0.037) and macular dragging (7 vs 1, p=0.039) were observed in the laser-treated and injection-treated groups, respectively, but no systemic or neurodevelopmental adverse events were reported. In the ranibizumab group, 95.6% showed fully vascularised retinas. Multivariate analyses revealed that birth weight (OR 0.993, p=0.023) and higher ROP stage (OR 11.222, p=0.008) influenced the incidence of major complications.ConclusionIntravitreal ranibizumab for ROP appears to achieve similar therapeutic effects than did laser photocoagulation, but with fewer surgical complications such as retinal detachment or macular dragging.

scholarly journals Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity

2019 ◽  
Vol 28 (6) ◽  
pp. 526-532 ◽  
Author(s):  
Tariq Aldebasi ◽  
Muataz A. Guma ◽  
Rabia Bashir ◽  
Saif Al Saif ◽  
Waleed A. Altwaijri ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Single Injection ◽  
Case Series ◽  
Severe Hypoglycemia ◽  
Stage Iii ◽  
Complete Regression ◽  
Intravitreal Ranibizumab ◽  
Retrospective Case ◽  
Case Series Study ◽  
Medical City

Objectives: To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). Methods:We conducted this retrospective case series study at King Abdul Aziz Medical City, Riyadh, Saudi Arabia. Seventy-four eyes of 37 preterm infants with ROP stage III with plus disease in zone I, posterior zone II, and aggressive posterior ROP received a single injection of 0.3 mg intravitreal ranibizumab. The favorable outcome measure was complete regression of the disease with normal vascularization of the retina of those infants. Results: The gestational age of the 37 included cases was in the range of 23–28 weeks and their body weight at birth was between 510 and 1,235 g except for one case with 2,550 g under oxygen therapy <7days with severe hypoglycemia. All eyes showed a favorable response in terms of regression of plus disease from the first day after treatment, followed by regression of stage III retinopathy. All patients developed complete vascularization over variable periods of time. Conclusion: One injection of 0.3 mg intravitreal ranibizumab is effective in treating ROP stage III mainly in zones I and II.

Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity

2019 ◽  
pp. 112067211988698
Author(s):  
Nedime Sahinoglu-Keskek ◽  
Imren Akkoyun ◽  
Birgin Torer
Keyword(s):  
Birth Weight ◽  
Gestational Age ◽  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Primary Treatment ◽  
Primary Therapy ◽  
Case Review ◽  
Intravitreal Ranibizumab ◽  
Retrospective Case ◽  
Injection Zone

Objectives: To report the results of intravitreal ranibizumab injection as primary therapy in aggressive posterior retinopathy of prematurity, the process of the disease, and the additive treatments performed. Methods: This retrospective case review included 15 eyes of 8 premature babies with aggressive posterior retinopathy of prematurity who were initially treated with intravitreal ranibizumab injection. The documented data were gestational age, birth weight, gender, postmenstrual age at intravitreal ranibizumab injection, zone of retinopathy of prematurity, reactivation time of disease, iris neovascularization, retinal hemorrhage, anatomical outcome, and additional treatment. Results: Median gestational age at birth was 26 (range, 23–27) weeks, birth weight was 730 (range, 550–970) g, and postconceptional age at aggressive posterior retinopathy of prematurity diagnosis and intravitreal ranibizumab injection was 35 (range, 33–35) weeks. Intravitreal ranibizumab injection was performed as primary treatment. Two eyes necessitated a second intravitreal ranibizumab injection. The reactivation of retinopathy of prematurity was 5 (range, 3–7) weeks after intravitreal ranibizumab injection. Recurrence of the disease in Zone II was treated with laser photocoagulation. A favorable outcome was obtained in all eyes (100%). Conclusion: Aggressive posterior retinopathy of prematurity is a serious, rapidly progressing form of retinopathy of prematurity that requires quick and proper management. This study indicates that primary treatment with ranibizumab and laser photocoagulation on recurrence provide favorable anatomical outcomes.

Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect

2020 ◽  
pp. 112067212094510
Author(s):  
Marco H Ji ◽  
Darius M Moshfeghi ◽  
Ryan A Shields ◽  
Zachary Bodnar ◽  
Cassie A Ludwig ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Intravitreal Bevacizumab ◽  
Class Effect ◽  
Intravitreal Ranibizumab ◽  
Retrospective Case ◽  
Avascular Area ◽  
Peripheral Ischemia ◽  
Stage Disease ◽  
Postmenstrual Age

Purpose: To determine if fluorescein angiographic (FA) findings after intravitreal ranibizumab (IVR) for retinopathy of prematurity (ROP) conform to a class effect previously described with bevacizumab. Methods: Single-center retrospective case series of all infants treated with 0.2 mg (0.02 mL) IVR for Type 1 ROP from July 2016 to November 2018. FA were obtained at 40, 52, 62, and 72 weeks of postmenstrual age (PMA) using wide-angle photography. FA images were analyzed and the peripheral avascular areas measured with ImageJ using a reference disc diameter (DD). Based on the extent of the avascular area and tortuosity of the retinal vessels all eyes were classified into four categories: complete vascular maturity (vascularization within 2 DD of the ora serrata), VAA (avascular area >2 DD of the ora serrata), VAT (avascular area >2 DD of the ora serrata and posterior tortuosity), and reactivation (recurrence of stage disease). Results: About 13 infants were enrolled and 24 eyes were available in this study. None of the eyes reached complete vascular maturity at an average PMA of 60 weeks, 7 (29%) eyes presented with VAA, 8 (33%) with VAT, and 9 (37.5%) reactivated. The reactivated eyes presented with the largest area of peripheral ischemia, followed by the VAT and then the VAA groups ( p = 0.02). Conclusion: IVR conforms to the previously described regression patterns following intravitreal bevacizumab for ROP indicative of a class effect. Follow-up using FA might help to optimize the management of these infants after injection of the drug.

scholarly journals Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity

2012 ◽  
Vol 3 (1) ◽  
pp. 136-141 ◽  
Author(s):  
Ágata Mota ◽  
Ângela Carneiro ◽  
Jorge Breda ◽  
Vitor Rosas ◽  
Augusto Magalhães ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation ◽  
Intravitreal Ranibizumab

scholarly journals Incidence and Risk Factors of Retinal Detachment after Laser Photocoagulation in Anterior Zone I Retinopathy of Prematurity

2009 ◽  
Vol 45 (1) ◽  
pp. 60
Author(s):  
Sang Woo Park ◽  
Jung Won Park ◽  
Dae Hyun Kim ◽  
Jae Kyoun Ahn ◽  
Yeoung Geol Park ◽  
...  
Keyword(s):  
Risk Factors ◽  
Retinal Detachment ◽  
Retinopathy Of Prematurity ◽  
Laser Photocoagulation

Comparative Assessment of Widefield Fundus Autofluorescence Patterns in Retinoschisis and Retinal Detachment

2020 ◽  
Vol 4 (4) ◽  
pp. 286-292
Author(s):  
Jessica L. Cao ◽  
Thais F. Conti ◽  
Grant L. Hom ◽  
Amy S. Babiuch ◽  
Tyler Greenlee ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Imaging Modality ◽  
Fundus Autofluorescence ◽  
Case Series ◽  
Comparative Assessment ◽  
High Variability ◽  
Retrospective Case ◽  
Data Points ◽  
Sd Oct

Purpose: This article characterizes widefield fundus autofluorescence (WF-FAF) patterns in retinoschisis (RS), retinal detachment (RD), and combined retinoschisis-detachment (RS/RD), and to correlate them with spectral-domain optical coherence tomography (SD-OCT) findings. Methods: A retrospective case series of 13 eyes with senile RS, RD, or RS/RD is presented. One eye underwent imaging of 2 areas within the retina, resulting in 14 data points. Independent, masked graders classified pathology on SD-OCT as RS, RD, or RS/RD and graded WF-FAF images for either hypoautofluorescent areas or mixed autofluorescence (AF) (hyper-AF, iso-AF, hyper-AF with hypo-AF, hyper-AF with iso-AF, or hypo-AF with iso-AF). Results: There was no statistically significant correlation between the autofluorescence pattern and the type of retinal abnormality ( P = .74). Conclusions: High variability was found in the characterization of WF-FAF in patients with RS and RD. SD-OCT remains the criterion-standard imaging modality in distinguishing RS from RD in clinically ambiguous cases.

scholarly journals Internal Limiting Membrane Peeling for Persistent Submacular Fluid after Successful Repair of Diabetic Tractional Retinal Detachment

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Byung Ju Jung ◽  
Sohee Jeon ◽  
Kook Lee ◽  
Jiwon Baek ◽  
Won Ki Lee
Keyword(s):  
Retinal Detachment ◽  
Case Series ◽  
Internal Limiting Membrane ◽  
Ilm Peeling ◽  
Effective Treatment Option ◽  
Retrospective Case ◽  
Tractional Retinal Detachment ◽  
Vascular Arcade ◽  
Pars Plana ◽  
Successful Repair

This study is for reporting the outcomes of internal limiting membrane (ILM) peeling on persistent submacular fluid (PSF) after otherwise successful pars plana vitrectomy (PPV) for diabetic tractional retinal detachment (TRD). In this retrospective case series, five consecutive patients (5 eyes) who exhibited PSF following successful repair of diabetic TRD were included. The second operation was performed to remove ILM. The area of ILM peeling was expanded up to the major vascular arcade. Only air tamponade was used. The median interval between the first PPV and the second PPV with ILM peeling was 4.8 months (range: 4–6 months). PSF resolved completely within one (2 eyes) or 2 months after ILM peeling. The median logMAR best-corrected visual acuity (BCVA) was improved from 1.00 (Snellen equivalent 20/200) to 0.70 (Snellen equivalent 20/100). In conclusion, wide ILM peeling is an effective treatment option for PSF subsequent to successful repair of diabetic TRD. ILM peeling might increase the elasticity of retina, thereby allowing the retina to flatten. This procedure can induce faster retinal reattachment in diabetic TRD involving the macula.

Mid-term prognosis of type I Boston keratoprosthesis reimplantation

2020 ◽  
pp. bjophthalmol-2020-317598
Author(s):  
Soumaya Bouhout ◽  
Marie-Claude Robert ◽  
Mona Harissi-Dagher
Keyword(s):  
Retinal Detachment ◽  
Retention Rate ◽  
Case Series ◽  
Type I ◽  
Light Perception ◽  
Visual Rehabilitation ◽  
Boston Keratoprosthesis ◽  
Kaplan Meier ◽  
Primary Endpoints ◽  
One Year

AimTo examine the mid-term visual and anatomical prognosis of patients who require reimplantation of a second Boston keratoprosthesis type 1 (B-KPro).MethodsRetrospective observational case series of 122 patients (141 eyes) who received a B-KPro at a single institution were reviewed. Eyes that underwent a second B-KPro were included in the study. Primary endpoints were B-KPro retention, final visual acuity 20/200 and loss of light perception. Secondary endpoints included the occurrence of postoperative complications.ResultsSeventeen eyes (12%) required a B-KPro reimplantation. Corneal melt was the most common indication for replacement (88%). Mean follow-up time after the second B-KPro was 4.4±2.1 years. The Kaplan-Meier analysis estimated the second B-KPro retention rate at 79% over 8 years. Retroprosthetic membrane (RPM, 53%) was the most common complication. Forty-one per cent of the eyes suffered from corneal melt following their second B-KPro. One year after the second B-KPro, 47% of the patients retained a vision 20/200. Seven eyes (41.2%) lost light perception, which was secondary to an inoperable retinal detachment in five cases. Four eyes (24%) developed phthisis following inoperable retinal detachment (n=3) or endophthalmitis (n=1).ConclusionB-KPro reimplantation is a potentially sight- and globe-saving procedure for eyes with B-KPro failure, but the prognosis is guarded. B-KPro reimplantation can salvage ambulatory vision in a third of patients while another third of patients progress to loss of light perception. RPM and retinal detachment were important obstacles to visual rehabilitation while recurrent corneal melt was responsible for most cases of anatomical failure.

Sign in / Sign up

Export Citation Format

Share Document